Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
With about a million people living with Parkinson’s disease In the United States – and 90,000 get new diagnoses every year – the race is in the medicine.
Researchers of the Sloan Kettering Cancer Center (MSK) announced progress on that front – they have developed a new therapy that uses stem cells to treat advanced Parkinson.
In phase 1 test, researchers used donated stem cells (taken from the embryo at an early stage) to create nerve cells (neurons) and transplant them into the brain of 12 Parkinson patients, according to a statement from the MSK.
The new Parkinson remedy has proven effective in clinical trials: ‘very encouraged’
Once the cells are injected, dopamine products, a brain hormone that helps move and coordination.
(One of the features of Parkinson’s low level of dopamine, which causes typical symptoms of shivering, stiffness, balance problems and difficulty in walking.)
About a million people live with Parkinson’s illness in the United States, and 90,000 get new diagnoses each year. (East)
After 18 months, the injected cells “stayed in the brain without serious side effects,” the researchers reported.
Based on the MDS-updrs-a-navy rating for the symptoms developed by the International Society of Parkinson and the Disorders of the Movement-SUBDIPRESSE have experienced “noticeable improvement”, especially the group that has received a a higher dose.
Patients in a high -dose group reported 2.7 hours of additional “on time” every day.
“Neurologists say that things are usually worse with this disease, which means that the result is growing by a few points,” co-authored co-author Lorenz Studer, MD, Director of the MSK Center for Bit of Stem cell biology.
“In our study, not only did the result worse, but it dropped by more than 20 points in a high -dose group.”
Researchers used donated stem cells (taken from an early stage embryo) to create nerve cells (neurons) and transplant them into the brain of 12 Parkinson patients. (East)
On average, patients in a high-dose group reported about 2.7 hours of additional “on time”-which indicates periods of normal functioning with minimal symptoms-“a result that could be quite meaningful about their daily lives,” Studer remarked.
Given the success of the phase 1 experiment, the US Food and Medicines Administration (FDA) approved the approval of the researchers to go straight to a Phase 3 clinical trial In a much larger group of patients – about 100 people – which will take place in the first half of 2025.
The discoveries were published in Nature.
Parkinson’s cases could be doubled globally by 2050, the study reveals
“The study found that developing specific nerve cells from human embryonic stem cells in the laboratory, and then injection them into the brain of people with Parkinson’s disease, safely and has a significant promise as a Possible future treatment“Author of leading Studies Viviana Tabar, MD, President of the Neurohirurge Department at the Sloan Kettering Cancer Memorial Center in New York, told Fox News Digital.
“The discoveries were useful, because this work has been emerging for more than ten years.”
‘The main step forward’
Dr. Mary Ann Picone, Medical Director of the MS Center at Holy Nama Medical Center in Teaneck, New Jersey, said that cells for the treatment of Parkinson’s disease could offer the potential not only to slow down disability, but also to stop the progress and adoption of the motor function improvement.
“Although the risk is involved in immune suppression before stem cell implantation And the procedure itself, it would be the main step forward in replacing dopaminergic neurons lost in diseases, “said Picone, who was not involved in the studio, for Fox News Digital.
Click here to get the Fox News app
Levodopa, currently treatment for Parkinson, is limited in the fact that patients need larger amounts of dosage because time is passing, according to Piconee- “and regulating and on periods of rigidity or dyskinesia (uncontrolled muscle movements) become more severe.”
After 18 months, the injected cells “stayed in the brain without serious side effects,” the researchers reported. (East)
Dr. Ann Murray, Director of Movement Disorders on WVU Rockefeller Institute Neuroscience Institute in Western Virginia, called the studio “incredibly exciting“For Parkinson’s patients.
“Although the goal of this particular research project was to ensure security, to achieve a significant clinical improvement by UPDRS is absolutely revolutionary,” Murray told Fox News Digital. (Also not included in the studio.)
Click here to sign up for our Health Bulletin
“This is just the first step in getting this type of therapy approved for patients suffering from Parkinson’s disease, but this is an amazing first step for potential benefits of Brain therapy. “
Potential limitations
There were certain restrictions related to the study, Tabar noted.
“This is a small study that is intended to show safety-it is a higher, well-controlled study to prove that the treatment is really acting, an otherwise called Phase 3” Efficiency, “she said.
“This is an amazing first step for potential advantages of brain therapy for stem cells.”
These wound findings, however, “suggest a strong promise.”
“I think we can finally say that stem cells, when properly executed and distinguished, maintain a great promise to repair the brain in Parkinson’s and potentially in Other conditions One day, “Tabar said.
For more health articles, visit www.foxnews.com/health
Cell therapy was developed in MSK -Ui was licensed for Bluerock therapist at Massachusetts, which funded the studio.
